Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Oct 19 · above the Ichimoku cloud · RSI 79 (overbought) · MACD above its signal · at its 52-week high
| 19.66 | R3 (classic) | +0.39% |
| 19.63 | R2 (classic) | +0.27% |
| 19.61 | Previous day high | +0.15% |
| 19.61 | 52-week high | +0.15% |
| 19.61 | R1 (classic) | +0.14% |
| 19.58 | Pivot | +0.02% |
| 19.58 | Price now | |
| 19.56 | Previous day low | −0.10% |
| 19.56 | S1 (classic) | −0.12% |
| 19.53 | S2 (classic) | −0.24% |
| 19.51 | S3 (classic) | −0.37% |
| 15.28 | Previous month high | −21.96% |
| 10.65 | Previous month low | −45.61% |
| 10.35 | Previous week high | −47.11% |
| 8.66 | Previous week low | −55.77% |
| 4.19 | 52-week low | −78.60% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $185.9K | 0.00% | 16.93K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SLN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for SLN.
TimeframesUp on the hourly and weekly, mixed on the daily and monthly.
over a rising 21 EMA, 21 over 50
bouncing over the 21 EMA
over a rising 21 EMA, 21 over 50
bouncing over the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.7 | 12.9 | -3.1 | 38.7 | -5.6 | 59.1 | -4.5 | 29.0 | -19.2 | 79.1 | +222.0% | ||
| 2025 | -22.5 | -15.6 | -37.3 | 31.2 | 57.8 | -0.7 | 6.2 | -21.9 | 7.9 | 38.0 | -5.9 | -9.8 | −11.6% |
| 2024 | 29.6 | 13.1 | -15.2 | 1.2 | -4.0 | -9.5 | 7.9 | -6.9 | -4.8 | -4.8 | -54.2 | -13.1 | −60.4% |
| 2023 | -14.8 | -9.8 | -47.1 | 8.1 | -20.7 | 3.6 | 8.4 | 49.3 | 10.3 | -31.8 | 92.1 | 35.0 | +13.9% |
| 2022 | -12.1 | -12.9 | 3.8 | -36.0 | -24.1 | 28.4 | -13.9 | -0.9 | -0.7 | 14.8 | 36.1 | -2.7 | −36.2% |
| 2021 | 13.6 | 1.0 | -8.9 | 9.4 | 9.1 | -4.7 | -2.2 | -9.8 | -10.8 | 6.7 | 6.9 | 1.7 | +8.6% |
| 2020 | -13.3 | 20.0 | 22.2 | +27.1% |
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Buy / hold / sell counts